Drug Profile
Research programme: Eg5 antisense oligonucleotides - Isis Pharmaceuticals
Latest Information Update: 11 Feb 2011
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Class
- Mechanism of Action KIF11 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 01 May 2006 Preclinical trials in Cancer in USA (unspecified route)